AbbVie Inc. - Depositary Receipt (ABBV)

Profile

https://www.abbvie.com

AbbVie Inc. - Depositary Receipt is an unsponsored depositary receipt representing common stock of AbbVie Inc., a global biopharmaceutical company. It enables investors in specific markets to gain exposure to AbbVie's shares without direct ownership on the primary exchange. AbbVie Inc. focuses on discovering, developing, manufacturing, and commercializing innovative medicines, primarily in immunology, oncology, neuroscience, eye care, and virology. Key products include blockbuster drugs like Humira (adalimumab) for autoimmune diseases, Skyrizi and Rinvoq for inflammatory conditions, Imbruvica for blood cancers, and Venclexta for hematologic malignancies. The company generates substantial revenues, with 2024 total revenues reaching $56.3 billion and operating income of $18.3 billion. Financial metrics highlight operational efficiency, including a Piotroski F-Score of 9/9 indicating strong fundamentals, ROE around 0.35, and consistent free cash flow generation exceeding $19 billion in recent years. AbbVie Inc. - Depositary Receipt plays a vital role in providing diversified access to the pharmaceutical sector's growth, particularly in high-demand therapeutic areas shaping global healthcare.